DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Tegafur-uracil is an investigational drug.
There have been 79 clinical trials for Tegafur-uracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.
The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Taiho Oncology, Inc., and Fudan University.
There are four hundred and twenty-seven US patents protecting this investigational drug and three international patents.
Recent Clinical Trials for Tegafur-uracil
|Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer||Fudan University||Phase 2|
|SOX-based CRT for Esophageal Cancer.||Zhejiang Provincial People’s Hospital||Phase 1/Phase 2|
|Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC||The First Affiliated Hospital with Nanjing Medical University||Phase 3|
Top disease conditions for Tegafur-uracil
Top clinical trial sponsors for Tegafur-uracil
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tegafur-uracil||Start Trial||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Start Trial|
|Tegafur-uracil||Start Trial||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Tegafur-uracil||Start Trial||Molecular constructs with targeting and effector moieties||Start Trial|
|Tegafur-uracil||Start Trial||Glutaminase inhibitors and method of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tegafur-uracil||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|